+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07170995

Phase III Trial Comparing SHR-8068 with Adebrelimab and Chemotherapy Versus Tislelizumab with Chemotherapy for First Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-11-18

460

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy compared to tislelizumab combined with platinum-based chemotherapy as first-line treatments for patients with advanced or metastatic non-small cell lung cancer. This Phase III, randomized, open-label, and controlled study involves multiple centers and aims to find better treatment options for this serious lung cancer type. Participants will be randomly assigned to receive either SHR-8068 with adebrelimab and platinum-based chemotherapy or tislelizumab with platinum-based chemotherapy. Both treatment combinations will be given as initial therapy for locally advanced or metastatic non-small cell lung cancer. The study looks at the treatments over a planned period, assessing response and safety in participants. During the trial, participants will undergo evaluations including tumor assessments to measure progression-free survival and overall survival up to approximately 32 and 64 months, respectively. Other assessments include response rates, duration of response, adverse event monitoring, and quality of life measurements related to lung cancer symptoms. The study involves regular follow-ups and monitoring to track treatment effects and participant well-being throughout the study duration.

CONDITIONS

Brief Title

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Team

W

Weixia Li

Y

Yang Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here